RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will initiate a new clinical program in pancreatic cancer which will be led by Dr. Daniel D. Von Hoff. Dr. Von Hoff is Physician-in-Chief at the Translational Genomics Research Institute (“TGen”) and Professor of Medicine at both the Mayo Clinic and the University of Arizona College of Medicine.
20181101-HBP-Press-Release-New-Pancreatic-Clinical-Program-FINAL.pdf